Aptadir Therapeutics

Company Overview

Italian biotech company Aptadir Therapeutics is trying to switch silenced genes back on. Its molecules, DNMT-interacting RNAs (DiRs), are designed to block the abnormal DNA methylation that shuts down a single gene, rather than stripping methylation across the whole genome as older drugs do. The Milan company is privately held and preclinical. On September 29, 2026 it closed a seed round of €40 million ($45 million) led by 4BIO Capital, and the money goes first to CAP1-FMR1 in Fragile X syndrome. The science is well published; what the round has to buy is evidence that results in patient-derived models carry over into people.

Headquarters and Global Presence

Aptadir is registered in Milan, which is where its backers are: EXTEND, the hub that created it, and most of its seed investors are Italian. The science is international, drawn from the Beth Israel Deaconess Medical Center of Harvard Medical School, Italy's National Research Council (CNR), the Cancer Science Institute of Singapore and City of Hope National Medical Center.

Founding and History

Aptadir launched on September 24, 2024 as the first company created by EXTEND, the Italian technology transfer hub set up by CDP Venture Capital SGR with Angelini Ventures and Evotec (ETR: EVT), which put in $1.6 million of pre-seed money. It rests on a 2013 Nature paper by Annalisa Di Ruscio and colleagues showing that DiRs block gene-specific DNA methylation.

Therapy Areas and Focus

Aptadir works on diseases caused not by a broken gene but by a silenced one. Its first target is Fragile X syndrome, a genetic condition that causes intellectual disability, learning difficulties and developmental delays. In Fragile X, methylation switches off the FMR1 gene on the X chromosome and cuts production of FMRP, a protein the brain needs to develop and work normally. Cancer is the second front: the pipeline names myelodysplastic syndrome (MDS), a group of blood cancers that can progress to acute myeloid leukemia, and non-small cell lung cancer (NSCLC). The company also lists myotonic dystrophy, amyotrophic lateral sclerosis and Alzheimer's disease as possible uses, which shows the reach of the idea more than a plan.

Technology Platforms and Modalities

DNA methyltransferase 1 (DNMT1) is the enzyme that keeps methylation marks in place as cells divide. Drugs that inhibit it act across the genome, and in Aptadir's own account their effects are short-lived, toxic and not gene-specific. The platform comes in two forms. The first, aptaDiR, is a modified short RNA that soaks up DNMT1 for broad inhibition without the cell toxicity of existing drugs. The second, captaDiR, fuses that RNA to a gene-specific sequence so that only the targeted locus is affected. The second form is the point: if one gene can be reactivated and the rest left alone, the approach becomes a precise medicine rather than a blunt one. The design was set out in Nature Communications in 2023.

Key Pipeline and Programs

CAP1-FMR1 is the lead candidate, built to reactivate FMR1 in Fragile X syndrome. Aptadir says it has restored gene expression and normal biological function in patient-derived disease models, and the seed round is meant to take it toward the clinic. The release sets no date. Giovanni Amabile, the chief executive, has told Corriere della Sera that the company aims to begin its first patient study within 18 months.

The order of the pipeline has changed. At the 2024 launch the first program was Ce-49 in MDS, with a stated aim of entering the clinic by the end of 2025. There is no sign that it did: the trial registry holds no study for Aptadir or for either candidate, and the 2026 release does not mention Ce-49. MDS stays in the company's description and on its pipeline, alongside NSCLC and an undisclosed metabolic program. Every asset is preclinical, and the switch to a childhood genetic disease as the lead is the biggest strategic call the company has made so far.

Recent Developments

On September 29, 2026 Aptadir closed its €40 million seed round. 4BIO Capital led, and EXTEND followed on from its pre-seed stake. CDP Venture Capital invested through its Digital Transition Fund, joined by Indaco Venture Partners, XGEN Venture, CE-Ventures, Kerna Ventures, Italian Angels for Biotech and members of Club degli Investitori, with Angelini Ventures also investing directly. The funds will advance the RNA pipeline with CAP1-FMR1 first, and the chief executive has told Corriere della Sera that the company plans to hire more than 20 people. For a company that raised $1.6 million two years earlier, it is a change of scale.

Key Personnel

Giovanni Amabile, founder and chief executive, joined as executive chairman and acting chief executive at the 2024 launch. He previously ran Enthera and, as chief scientific officer at ADIENNE, achieved US approval for thiotepa in 2017. The scientific founders are Annalisa Di Ruscio, with more than 15 years in RNA biology and DNA methylation; Daniel Tenen, a leukemia researcher; Vittorio De Franciscis, an aptamer specialist; and Marcin Kortylewski, who works on oligonucleotide immunotherapeutics. Simone Braggio, a pharma and contract research veteran, and Davide Santi, a healthcare investor, sit on the board.

Strategic Partnerships

Aptadir's closest tie is to EXTEND, which spun it out, funded it first and is chaired by Claudia Pingue, head of the Technology Transfer fund at CDP Venture Capital. Through EXTEND the company is linked to Evotec and Angelini Ventures. Neither release discloses a licensing or pharma partnership, so the investors are the partners for now.

FAQ Section